Screener
Jade Biosciences JBIO Foreign currency translation gains (losses)
Foreign currency translation gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax expense | (16) | — |
| Net loss | $(40,368) | $(38,169) |
| Other comprehensive income (loss): | ||
| Currency translation adjustment | 2 | — |
| Unrealized loss on investments | (473) | — |
| Comprehensive loss | $(40,839) | $(38,169) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.57) | $(12.10) |
| Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | $(573.44) | — |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's foreign currency translation gains (losses)?
- Jade Biosciences (JBIO) reported foreign currency translation gains (losses) of $2K in Q1 2026.
- What does foreign currency translation gains (losses) mean?
- This metric captures the gains or losses arising from the translation of financial statements of foreign subsidiaries from their functional currency into the reporting currency. It reflects the impact of exchange rate fluctuations on the value of international assets and liabilities. This figure is excluded from net income and instead reported as a component of comprehensive income.
Ask your AI about Jade Biosciences's foreign currency translation gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude